Treatment experiences with focus on IL-6R inhibition in patients with VEXAS-syndrome and a case of remission with azacytidine treatment.

Morten M JohansenDaniel El FassiChristoffer T H NielsenSophine B KrintelNiels GraudalJakob Werner Hansen

Published in: Rheumatology (Oxford, England) (2023)

IL-6Ri induces control of inflammatory symptoms and allows decreased prednisone usage in a large subset of VEXAS patients. However, most experience progressive bone marrow failure during IL-6Ri.Azacytidine could be a promising treatment strategy and warrants further investigation.

Keyphrases

bone marrow
end stage renal disease
chronic kidney disease
oxidative stress
newly diagnosed
mesenchymal stem cells
physical activity
prognostic factors
replacement therapy
sleep quality